Evaluate a Norstella company
Evaluate a Norstella company
Coming Soon Series 1
Data into direction, one therapy area at a time. Expert analysis of the market forces shaping biopharma’s pipeline priorities, built on Evaluate’s AI-enabled, proprietary data.
Alert me when new episodes drop

Series at a glance

7

Episodes

15-20 mins

Per episode

1

Available now

6

Therapy areas

Therapy areas

Oncology
CNS
Immunology
Cardiovascular
Cell & Gene
Metabolic
Notify me when new episodes are dropping

What to expect

Where biopharma is investing, where pipelines are shrinking, and what it means for therapy area strategy.

What the episode covers

  • Why the pipeline shrank in 2025
  • Which therapy areas are beating growth benchmarks
  • Where M&A money is concentrating
  • Oncology’s rising deal share, shrinking pipeline share
  • Which areas face the heaviest discontinuation risk
  • Where pipeline momentum is building

Episodes

Click any episode to watch. Each episode includes the video, a companion report, blog post, and additional resources.
Evaluate Spotlight: Oncology
Episode 1

Dropping Soon  ›

Evaluate Spotlight: CNS
Episode 2

Dropping Soon  ›

Evaluate Spotlight: Immunology
Episode 3

Dropping Soon  ›

Evaluate Spotlight: Cardiovascular
Episode 4

Dropping Soon  ›

Evaluate Spotlight: Cell and Gene
Episode 5

Dropping Soon  ›

Be first in line for every new episode

  • New Episode Alerts
  • Therapy Area Updates
  • Exclusive Evaluate Insight





Evaluate Consulting

Data into direction. Partnership into purpose.

Want to go deeper? Evaluate’s consulting team provides bespoke analysis on market sizing, pipeline strategy, BD&L, and competitive intelligence.

Learn more
Evaluate White Logo
Instagram Linkedin